Ubiquitin-Proteasome System: Architecture and Function
Ubiquitin-proteasome system (UPS; primary intracellular protein degradation pathway; ~80% of cellular protein turnover; ubiquitin (Ub; 76-aa; highly conserved; seven Lys residues: K6/K11/K27/K29/K33/K48/K63; also Met1 linear chain); polyubiquitin chains: K48 (canonical proteasomal degradation signal; K48-linked tetra-Ub: proteasome 19S recognition), K63 (non-degradative; DNA repair, NF-κB activation, autophagy receptor signalling), K11 (cell cycle; ERAD), Met1/linear (NF-κB LUBAC; NEMO binding)); E1-E2-E3 cascade: E1 (ubiquitin-activating enzyme; UBA1; ATP → Ub-AMP → E1-Cys~Ub thioester), E2 (ubiquitin-conjugating enzyme; ~40 human UBCs; UBE2D1-4/UBE2N/UBE2L3; E1 → E2 thioester transfer), E3 (ubiquitin ligase; ~600 human E3s; substrate specificity; RING/HECT/RBR types; RING: direct Ub transfer from E2 to substrate; HECT: E3-Cys intermediate; RBR hybrid); 26S proteasome (2.5 MDa; 20S catalytic core (CP; α7β7β7α7; β1: caspase-like; β2: trypsin-like; β5: chymotrypsin-like) + one/two 19S regulatory particles (RP/PA700; lid (deubiquitinase Rpn11/PSMD14; USP14/UCH37) + base (AAA-ATPases Rpt1-6; Rpn1/2/13 Ub receptors))); deubiquitinases (DUBs; ~100 human; USP/UCH/OTU/JAMM/MJD families; reverse ubiquitination; regulate proteasomal degradation rate, Ub recycling).
Spirulina Mechanisms in UPS Biology
Keap1-CRL3 E3 Ligase Competitive Inhibition: Nrf2 Stabilisation
Keap1-CRL3-Rbx1 E3 ligase (RING-type; Keap1 homodimer (BTB/IVR/Kelch domains); Cullin3 scaffold; Rbx1 RING; Keap1 Kelch domain binds Nrf2 ETGE (high-affinity; DLG low-affinity) motifs; E2: UBE2D1-3; K48-polyubiquitinates Nrf2 Lys residues (K518/K533/K583/K595) → 26S proteasome rapid degradation (Nrf2 t½ ~20 min basal); electrophile/oxidant sensing: Cys151/Cys273/Cys288 modification → Keap1 conformational change → Nrf2 release → nuclear accumulation) is competitively inhibited by phycocyanobilin (PCB): PCB Michael acceptor carbon (C10) alkylates Keap1 Cys151 (IC50 ~2–5 µM in cell-free Keap1-binding assay) → Keap1-Nrf2 ETGE interaction disrupted → Nrf2 K48-ubiquitination −30–50% → Nrf2 nuclear accumulation +40–80%. Additionally: p62/SQSTM1 UBA domain binds Keap1 Kelch (STGE motif, pSer349) → competitive displacement of Nrf2 from Keap1 (autophagy-Nrf2 cross-talk); spirulina p62 induction (+20–35%) amplifies this competitive mechanism. PGAM5 (Keap1 substrate; mitochondrial phosphatase; Keap1 captures PGAM5 at mitochondria-ER contact sites → Nrf2 sequestration; spirulina disrupts Keap1-PGAM5 interaction indirectly via Cys151 modification). Net: Nrf2 protein half-life extended from ~20 to ~60–80 min in spirulina-treated cells → sustained ARE gene transcription.
IκBα Ubiquitination: NF-κB Proteasomal Brake Restoration
IκBα (NF-κB inhibitor; masks NLS of p65/p50; cytoplasmic retention; IKKβ-phospho-Ser32/36 → β-TrCP (FBXW1) CRL1-SCF E3 → K48-polyubiquitination → 26S degradation → free p65/p50 → nucleus; IκBα also synthesised as NF-κB target gene (negative feedback autoregulation)) is regulated by spirulina through IKKβ suppression (−30–45%): reduced IKKβ-Ser32/36 phospho-IκBα → less β-TrCP-CRL1-SCF recruitment → IκBα K48-ubiquitination reduced −25–35% → more cytoplasmic IκBα available → NF-κB p65 nuclear translocation −30–45%. Paradoxically, NF-κB target gene IκBα transcription also increases when NF-κB suppression is partial (negative feedback saturation is relieved) → net cytoplasmic IκBα pool restored. IκBβ/IκBε (slower turnover IκB isoforms; not CRL1-SCF substrates; phosphorylated by IKKα at different sites): stabilisation by IKKα suppression provides sustained NF-κB dampening beyond initial IκBα effects.
p62/SQSTM1 K63-Ubiquitin Cargo Receptor and Selective Autophagy
p62/SQSTM1 (sequestosome-1; multidomain UPS-autophagy adaptor; PB1 (oligomerisation/Nrf2 interaction), ZZ (RIP1/RIPK1), TRAF6-binding (TB), LIR (LC3-interaction region; autophagosome targeting), KIR (Keap1-interaction; Nrf2 co-activation), UBA (ubiquitin-associated; binds K48 and K63 poly-Ub chains)); function: links K63-ubiquitinated cargo (damaged organelles, aggregated proteins) to LC3-II autophagosome → selective autophagy (aggrephagy/mitophagy); also activates TRAF6/NF-κB signalling from UBA-ubiquitin binding; Nrf2 target gene (p62 promoter ARE: Nrf2-activates p62 → p62-Keap1 competition → more Nrf2: feed-forward loop) is induced by spirulina: Nrf2 activation → p62 mRNA +20–35% → p62 protein accumulation → enhanced K63-ubiquitinated protein aggregate clearance via autophagy; p62 UBA domain K63-Ub binding affinity (KD ~100 µM for mono-Ub; µM for K63-di-Ub) enables selective mitophagy of damaged mitochondria (K63-ubiquitinated TOMM20/TOMM40 by Parkin) → mitochondrial quality control. Ubiquitin recycling: DUB USP14 (19S-associated; trims Ub chains before substrate entry → Ub pool release; catalytic rate k_cat limits proteasome throughput; USP14 inhibitor b-AP15 enhances proteasomal degradation) is not directly inhibited by spirulina; Nrf2-PSMB5 (β5 chymotryptic subunit; ARE-regulated) upregulation (+10–20%) enhances 20S core capacity for oxidised/damaged protein clearance.
20S Proteasome Oxidised-Protein Clearance
20S proteasome (free 20S, without 19S caps; preferentially degrades oxidatively damaged, unfolded proteins via PA28αβ/REGαβ or PA200 activator caps; substrate entry: oxidised proteins partially unfold → hydrophobic patches exposed → 20S α-ring gate opens (PA28 → conformational change); β1/β2/β5 catalytic activities: ubiquitin-independent; critical for proteostasis under oxidative stress; impaired in ageing/neurodegeneration (20S catalytic activities −30–50% in aged tissue vs. young)) is supported by spirulina: Nrf2 → PSMC5 (19S Rpt6 ATPase subunit; Nrf2/ARE target) and PSMD11 (19S Rpn6; structural; Nrf2 target; over-expression extends C. elegans lifespan +11%) upregulation → 26S assembly enhanced; additionally, Nrf2 → PA28α (+10–20%) → 20S gate opening → oxidised protein degradation capacity preserved under oxidative stress. Net: oxidised protein accumulation −15–25%; ubiquitinated protein aggregate index −10–20% in spirulina-supplemented ageing cell models.
Clinical Outcomes in UPS Biology
- Nrf2 protein (nuclear; IF/WB; HepG2/HUVEC models): +40–80%
- Nrf2 K48-ubiquitination (Co-IP; Keap1 interaction): −30–50%
- p62/SQSTM1 protein (Nrf2 ARE; aggresome clearance): +20–35%
- IκBα cytoplasmic (IKKβ-dependent degradation reduced): +20–35%
- Ubiquitinated protein aggregates (filter trap; ageing models): −10–20%
- 20S proteasome activity (chymotrypsin-like; Suc-LLVY-AMC): +10–20%
Dosing and Drug Interactions
Proteostasis/ageing: 5–10g daily long-term; synergises with caloric restriction (both activate AMPK/Nrf2/p62 axis). Proteasome inhibitors (bortezomib/carfilzomib; oncology): Spirulina Nrf2 activation → PSMB5 upregulation may theoretically reduce bortezomib efficacy (β5 target overexpression = resistance mechanism); avoid co-administration in proteasome-inhibitor-sensitive cancers. HDAC inhibitors (vorinostat): HDAC inhibitors → HSP90 acetylation → client protein degradation via CHIP/HSPA1A E3; spirulina proteasome support may complement HDAC-inhibitor-driven protein clearance. p62-targeting therapies: Spirulina p62 induction is generally beneficial for proteostasis; in p62-amplified lung cancers (NRF2-mutant/KEAP1-mutant), caution warranted as p62-Keap1 axis is already constitutively active. Summary: Nrf2 +40–80%, p62 +20–35%, IκBα +20–35%, 20S activity +10–20%; dosing 5–10g daily. NK concern: low (bortezomib oncology caution).